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a  b  s  t  r  a  c  t
Comparative  risk  assessment  for  Chronic  Obstructive  Pulmonary  Disease  (COPD)  among  current,  former
and non-smokers  categories  remains  controversial  and not  studied  in  detail.  We  conducted  a meta-
analysis  to  summarize  all the  relevant  published  studies  on  this  topic  and  to update  the  association
between  smoking  and  prevalence  of  COPD  in current,  former  and  non-smokers.  Identiﬁcation,  screening,
eligibility  and  inclusion  of  articles  for  the study  were  conducted  as  per  the Preferred  Reporting  Items
for  Systematic  Reviews  and  Meta-Analysis  (PRISMA)  guidelines.  Quality  assessment  of included  studies
was  undertaken  using  a scoring  sheet.  Meta-analysis  after  the  ﬁnal  synthesis  of  the  selected  studies  was
performed  using  the  STATA  and Comprehensive  Meta-Analysis  (CMA)  software.  Estimates  from  forty  two
independent  studies  reporting  547,391  individuals  were  identiﬁed.  Twenty  two  studies  were  conducted
in  Europe,  nine  in America  and  ten in Asia  and one  from  New  Zealand.  The  meta-analysis  showed  that  the
prevalence  of COPD  was  signiﬁcantly  higher  in  current  smokers  compared  with  former  and  non-smokers.
However,  owing  to  large  heterogeneity  among  the  estimates  obtained  from  the  studies,  stratiﬁcation  was
done with  respect  to continent,  diagnostic  criteria  of COPD  and  study  design  which  also  showed  similar
results.  The  stratiﬁed  analysis  also  revealed  similar  trend  of  results  with  prevalence  of COPD being higher
in current  smokers  as  compared  to former  and  non-smokers.  The  present  meta-analysis  highlights  the
positive  association  between  smoking  and  COPD  prevalence.  There  is  an  urgent  need to implement  more
effective  policies  towards  the  restriction  of tobacco  use,  to reduce  the  burden  of COPD.©  2015  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an  open  access  article  under  the CC
BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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. Introduction
The Global Initiative for Chronic Obstructive Lung Diseases
GOLD) has classiﬁed Chronic Obstructive Pulmonary Disease
COPD) as a diseased state characterized by airﬂow limitation that
s not fully reversible and which is also associated with abnor-
al  inﬂammatory responses of the lungs to noxious particles or
ases [1]. According to the Global Burden of Disease (GBD), COPD
s the third leading cause of death in the world after ischemic
eart disease and stroke, with 2.75 million deaths worldwide and
redicted to further increase the mortality in the coming years
2]. In 1990, COPD was ranked sixth among all causes of death
orldwide and by 2030 it is projected to be at the third posi-
ion [3]. COPD is responsible for 5.5% of deaths globally, and this
ercentage rises to 6.06% for developing countries, as opposed
o 3.78% in the developed countries. GBD study also attributes
.09% of total Disability Adjusted Life Years (DALYs) globally
nd 3.12% of the total DALYs in developing countries to COPD
4].
Tobacco smoke exposure is one of the most signiﬁcant fac-
ors for COPD with 80–90% of all cases attributable to smoking
5]. Pipe and cigar smoking have also been found to be associ-
ted with increased COPD risk, but less threatening than cigarette
moking [1,6,7]. Though cigarette smoking is one of the most sig-
iﬁcant causes of COPD, it accounts for about 20% of clinically
igniﬁcant COPD [1,6–8]. Male gender, advanced age, occupa-
ional exposure and low socio-economic status are some of the
ther well-known risk factors of COPD [9,10]. In high and mid-
le income countries, tobacco smoke is the prime risk factor,
hile in low income countries exposure to indoor air pollution,
uch as the use of biomass fuels for cooking and heating causes
he burden of COPD [11]. Some developing countries have exhib-
ted higher mortality levels among non-smokers, for example in
hina there is a much higher risk of death from COPD among
on-smokers [12]. Data from the third National Health and Nutri-
ion Examination Survey, carried out between 1988 and 1994,
evealed that 24.9% (plus or minus 1.4%) Americans with COPD
ere never smokers. The United Kingdom and Spain reported sim-
lar ﬁndings of 22.9% and 23.4%, respectively. Never-smokers with
OPD were 5.6% out of a study population of 4291 participants
13,14].
The development of COPD is multifactorial and genetic fac-
ors are important risk factors for COPD. Alpha1-antitrypsin
eﬁciency is an established genetic cause of COPD especially
n the young and it has been reported that 1-antitrypsin
eﬁciency occurs in 1–2 per cent of individuals with COPD
15]. . .  .  . .  . . .  . . . .  .  .  . . . .  . . .  . . .  . .  .  . . . .  .  . . .  .  . . .  . . .  .  . .  .  . . .  .  .  . . . . . .  . . .  . .  .  .  . .  .  . . . . . .  .1073
Considering the risk of current, former and non-smokers on
the morbidity of COPD from earlier reports, we have conducted
a meta-analysis to estimate the association between smoking
and prevalence of COPD in general population based on different
smoking criteria. To the best of our knowledge, this is the ﬁrst
evidence-based meta-analysis on the global comparison of COPD
morbidity among current, former and non-smokers. The variations
due to different diagnostic criteria of COPD, study locations and
study designs have been analyzed in the present study. This study
can be utilized by policy holders for the effectiveness of their poli-
cies towards reduction of COPD.
2. Material and methods
2.1. Search Strategy
We searched the publications listed in the electronic database
(source: PubMed, January 1, 1990–June, 2014) and Google Scholar
(source: http://www.scholar.google.co.in) using the following text
and key words in combination both as MeSH terms and text
word “COPD”; “smokers”; “health”; “risk” or “factors”; “diagnostic”;
“burden”; “exposure”; “disease” or “prevalence” or “morbidity”
or “disability”; “mortality”; “tobacco”; “smoking”; “smoke”. The
search was limited only to articles in English. The search was lim-
ited to PubMed and Google Scholar due to the non-accessibility of
Medline and Embase.
2.2. Study Selection
Identiﬁcation, screening, eligibility, inclusion of articles and
meta-analysis for the study follows Preferred Reporting Items for
Systematic Reviews and Meta-Analysis (PRISMA) [16]. The system-
atic review protocol for PRISMA was based on the information
available at http://www.prisma-statement.org/statement.htm
Inclusion of the published articles for the study was based on
the following criteria:
1. Design of the study: case control, cohort and cross-sectional
studies.
2. Studies that contained the minimum information necessary to
estimate the number of subjects in the smoking groups (current,
former and non-smokers).3. Methodology details in publication with mention of sampling
strategy, study design, approach of diagnosis and diagnostic
criteria used by the investigators should be available in the lit-
erature.
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Articles identified in the 
preli minar y search         
(Total N = 3013)
Articles screened     
(N = 1220)
Articles accepted     
(N = 42)
Total articles accepted      
)
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Fig. 1. Flow chart for the i
. Availability of data on the number of COPD subjects in the smok-
ing groups (current smokers, former and non-smokers).
. Deﬁnition for smoking: current, former and non-smokers.
. Studies with environmental tobacco smoke exposure were also
included.
The exclusion criteria for the selection was following
. Design of the study: randomized control trials, intervention
study
. Articles in languages other than English.
. Subjects/patients with multiple diseases like COPD and TB, COPD
and emphysema, alveolitis, SARS, HIV, metabolic disorders, car-
diovascular disorders, gastrointestinal diseases and tumor.
.3. Data abstraction
Articles were reviewed and cross checked independently by two
uthors (RK, CNK). Percentage agreement between the authors on
he quality review ranged between 90% to 100%. Any disagreements
ere resolved by consensus of all authors. Data on the following
haracteristics were independently extracted: sample size, author’s
ame, year of publication, study design, sample size, age group,
tudy locations as continents (deﬁned as Europe, America or Asia),
ccupation, gender category, number of COPD cases with respect
o smoking status (current, former and non-smokers) and diag-
ostic criteria of COPD (Spirometry, patient reported diagnosis,
hysician diagnosis, questionnaire-based diagnosis). Information
iven above were collected and evaluated for quality and then
ross-checked.
.4. Quality assessment
Quality assessment of ﬁnal included studies were conducted
sing a scoring sheet given as Table S1 (supplementary ﬁle) which
as prepared by authors (RK, CNK) and independently analyzed
nd outcome results were discussed and reached a consensus.
.5. Data analysisOdds ratio was used to determine the association between
moking and the prevalence of COPD. The heterogeneity among
he included studies was evaluated using the 2-based Q statisticon of articles in the study.
test. In the case of heterogeneity, random effects model was used
for the analysis or else a ﬁxed effects model was used.
Subgroup analysis were performed to investigate poten-
tial sources viz., continent wise stratiﬁcation (American,
Asian and European), diagnostic criteria for COPD (Spirome-
try/Bronchodilator, Physician diagnosis/Questionnaire) and study
design (Cross-sectional, Cohort and Case-Control), for analysis of
between–study heterogeneity. The present study was  approved
and registered by the International Prospective Register of System-
atic Reviews (PROSPERO), National Institute for Health Research
(PROSPERO Registration No.: CRD42013005696). Meta-analysis
was performed and forest plot were prepared using STATA (IC 13,
StataCorp LP, TX, USA) and Comprehensive Meta-Analysis (CMA)
software (USA, version 2.2.064). The criterion for signiﬁcance was
set at p < 0.05. Potential for publication bias was assessed with
funnel plots, by Egger’s regression asymmetry test [17] using CMA
software.
3. Results
3.1. Study selection
With the search strategy, 3013 unique citations were initially
retrieved. Of these, 1220 articles were considered of interest and
full text was retrieved for detailed evaluation.1178 of these 1220
articles were subsequently excluded and ﬁnally 42 articles were
included in the meta-analysis. The detailed ﬂowchart for the inclu-
sion of articles is presented in Fig. 1.
3.2. Study characteristics
The characteristics (author’s name, year, methodology, num-
ber of subjects, age group of study subjects and country) of the
included articles in the study are shown in Table 1. Forty two stud-
ies reporting 547,391 individuals consisting of current, former and
non-smokers were identiﬁed. Twenty two  studies were based in
Europe, nine in America, ten in Asia and one from New Zealand.
After the ﬁnal synthesis of literature, 42 articles were used for the
meta-analysis (Table 1). Since there was only one case-control stud-
ies and one report based on hospital admission, these studies were
not included due to constraints in stratiﬁed analysis. One study
from New Zealand was not included in the stratiﬁed analysis.
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Table  1
Characteristics of the studies included in the meta-analysis.
Author name Year Gender Method used Country No. of subjects Age group
A. Johannessen [34] 1996 Male and Female Spirometry Norway 2235 15–70
A.  Johannessen [35] 2004 Male and Female Spirometry Norway 908 Mean age 41.2
A.  Menezes [36] 2005 Male and Female Spirometry and Bronchodilator Brazil 1000 >40
A.  Menezes [36] 2005 Male and Female Spirometry and Bronchodilator Chile 1208 >40
A.  Menezes [36] 2005 Male and Female Spirometry and Bronchodilator Mexico 1063 >40
A.  Menezes [36] 2005 Male and Female Spirometry and Bronchodilator Uruguay 943 >40
A.  Menezes [36] 2005 Male and Female Spirometry and Bronchodilator Venezuela 1357 >40
A.  Caballero [37] 2008 Male and Female Spirometry Columbia 5539 >40
A.  Lindgren [38] 2009 Male and Female Questionnaire Sweden 9319 18–77
A.  Johannessen [39] 2012 Male and Female Spirometry Norway 758 40–79
A.  Lindberg [40] 2006 Male and Female Spirometry Sweden 963 46–77
A.  Lindberg [41] 2006 Male and Female Spirometry Sweden 1237 46–77
B.  Lundback [42] 2003 Male and Female Spirometry Sweden 1282 >46
C.  Iribarren [43] 1999 Male and Female Questionnaire USA 17774 30–85
D.M.  Mannino [44] 2003 Male and Female Spirometry USA 7503 >17
D.  Coultas [45] 2001 Male and Female Spirometry USA 5743 >45
D.  Price [46] 2006 Male Spirometry UK 572 >40
D.  S. Kim [47] 2005 Male and Female Spirometry Korea 3981 >45
D.  S. Kim [48] 2006 Male and Female Spirometry Korea 9243 >18
FeiXu [49] 2005 Male and Female Physician diagnosis China 29319 >35
J.A.  Dickinson [50] 1999 Male and Female Spirometry England 500 60–75
J.  Hardie [51] 1998 Male and Female Physician diagnosis Norway 1649 >70
K.  Tsushima [52] 2005 Male and Female Spirometry Japan 2246 mean age 53.7
K.  M.  Bang [53] 1993 Male and Female Spirometry USA 585 mean age 47.8
L.  Shahab [54] 2006 Male and Female Spirometry England 8215 >35
L  .Trupin [55] 2003 Male and Female Physician diagnosis USA 2061 55–75
M.  Miravitles [56] 2009 Male and Female Spirometry Spain 4274 40–80
M.  Miravitlles [57] 2005 Male and Female Spirometry Spain 363 40–69
M.  D. Eisner [58] 2005 Female Physician diagnosis USA 2113 55–75
M.  P. Purdue [59] 2006 Male Spirometry USA 176997 >20
M.  Bednarek [60] 2005 Male and Female Spirometry Poland 676 41–72
N.  Zhong [61] 2007 Male and Female Spirometry China 20245 >40
P.  Salameh [62] 2012 Male and Female Questionnaire/Spirometry Lebanon 833 >40
P.  Vineis [63] 2005 Male and Female Physician diagnosis Europe 123479 35–74
P.  Danielsson [64] 2012 Male and Female Spirometry Sweden 548 > 40
P.  S. Bakke [65] 1991 Male and Female Spirometry Norway 1275 15–70
P.  Johnson [66] 2008 Female Spirometry India 900 30–70
R.  de Marco [67] 2003 Male and Female Spirometry Europe 14855 20–44
R.  Isoaho [68] 1994 Male and Female Questionnaire Finland 1196 >64
R.P.  Young [69] 2009 Male Spirometry New Zealand 654 >40
S.  Kojima [70] 2005 Male and Female Spirometry Japan 11460 25–74
S.  Liu [71] 2007 Male and Female Spirometry China 3286 >40
T.  Schikowski [72] 2005 Female Spirometry Germany 4757 54–55
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Z.  J. Anderson [75] 2010 Male and Female Hospital discharge register for th
.3. Quality assessment of included studies
The quality assessment of included studies showed high score
or 36 studies out of 42 studies. Rest 6 studies are in the moderate
ategory as per the quality assessment tool.
. Comparison of COPD among current smokers and
on-smokers
.1. Pooled analysis
Forty one estimates were obtained to compare the COPD status
n current and non-smokers (Fig. 2). Due to the marked heterogene-
ty among the ORs (p<0.001), a random effects model was  used and
howed that the prevalence of COPD was signiﬁcantly higher in cur-
ent smokers compared with non-smokers (overall OR = 3.26; 95%
I, 2.67–3.98; z = 11.51, p < 0.001) (Table 2 and Fig. 2). The forest
lot analysis revealed the rhomboid of the overall effect show-
ng higher prevalence of COPD in current smokers as compared to
on-smokers.Sweden 4280 18–77
Japan 2343 >40
st hospital admission for COPD Denmark 52799 50–64
4.2. Stratiﬁed analysis with respect to study locations (Continent)
Owing to the large heterogeneity in the pooled analysis, strati-
ﬁed analysis was  performed according to different criteria to study
the patterns of the results obtained. Using random effects model, a
signiﬁcantly higher prevalence of COPD was observed for current
smokers as compared to non-smokers, for Asian studies (OR = 3.38;
95% CI, 2.37–4.90; z = 6.45, p < 0.001) (Table 2). Similar trend was
observed in studies of American and European origin, showing
signiﬁcantly higher prevalence of COPD in current smokers, for
American (OR = 2.21; 95% CI, 1.64–2.97; z = 5.24, p < 0.001) and for
European (OR = 4.25; 95% CI, 3.06–5.9; z = 8.61, p < 0.001) studies.
The forest plot analysis for Asian, American and European studies
depicted a similar trend while studying the rhomboid of the over-
all effect, with the analysis results depicting higher prevalence in
current smokers (Fig. S1).
4.3. Stratiﬁed analysis by diagnostic criteria of COPDA random effects model was used for the analysis of the
thirty two  estimates identiﬁed using Spirometry/bronchodilator
test for diagnosis of COPD due to signiﬁcant heterogeneity
(p < 0.001). Signiﬁcantly higher prevalence of COPD (OR = 2.91;
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NOTE:  Weights are from rand om effects analysis
Overall   (I-squared = 94.7%,  p = 0.000)
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(Fig. 2. Forest plot analysis for cu
5% CI, 2.51–3.38; z = 11.55, p < 0.001) was observed in current
mokers compared with non-smokers (Table 2). The random
ffects model used for the nine estimates from studies using
hysician diagnosis/questionnaire for the diagnosis of COPD
howed signiﬁcantly higher prevalence of COPD in current smok-
rs (OR = 4.36; 95% CI, 2.21–8.60; z = 4.26, p < 0.001) (Table 2).
 similar trend was observed in the forest plot analysis of
oth the studies using Spirometry and bronchodilator test for
he diagnosis of COPD. In the case of estimates from studies
sing physician diagnosis/questionnaire for the diagnosis of COPD,
he rhomboid represented higher prevalence in current smokers
Fig. S1). v/s non-smokers (pooled data).
4.4. Stratiﬁed analysis based on study design
Signiﬁcant heterogeneity was  observed among the thirty four
cross-sectional estimates obtained. Using a random effects model
for the analysis, the prevalence of COPD was found to be sig-
niﬁcantly higher in current smokers compared to non-smokers.
(OR = 2.97; 95% CI, 2.49–3.56; z = 12.01, p < 0.001) (Table 2). Five
estimates from cohort studies were considered for the meta-
analysis and heterogeneity was observed. A signiﬁcantly higher
prevalence of COPD in current smokers (OR = 4.69; 95% CI,
1.51–14.57; z = 2.67, p < 0.001) was  found using a random effects
model (Table 2). The overall effect of studies based on the study
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Table  2
Comparison of prevalence of COPD between current and non-smokers.
Current smokers v/s non-smokers
No. of estimates Heterogeneity test (Q Test) Odds ratio(OR) 95% C.I. Pooled OR Test (z test)
All 41 758.17, p < 0.001 3.26 2.67–3.98 11.51, p < 0.001
Continent
Asia  10 297.79, p < 0.001 3.38 2.37–4.90 6.45, p < 0.001
America 13 110.75, p < 0.001 2.21 1.64–2.97 5.24, p < 0.001
Europe 18 297.79, p < 0.001 4.25 3.06–5.90 8.61, p < 0.001
Diagnostic criteria
Spirometry/Bronchodilator 32 184.36, p < 0.001 2.91 2.51–3.38 11.55, p < 0.001
Physician diagnosis/questionnaire 9 580.58, p < 0.001 4.36 2.21–8.60 4.26, p < 0.001
Study  design*
Cross sectional 34 426.97, p < 0.001 2.97 2.49–3.56 12.01, p < 0.001
Cohort  5 196.65, p < 0.001 4.69 1.51–14.57 2.67, p < 0.01
* 1Case control study and 1Hospital based study not included in stratiﬁed analysis by study design.
NOTE:  Weights are from rand om eff ects  analysis
Overall  (I-squared = 96.8%, p = 0.000)
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Fig. 3. Forest plot analysis for current v/s former smokers (pooled data).
1070 R. Kamal et al. / Toxicology Reports 2 (2015) 1064–1074
Table 3
Comparison of prevalence of COPD between current and former smokers.
Current smokers v/s former smokers
No. of estimates Heterogeneity test (Q Test) Odds ratio(OR) 95% C.I. Pooled OR Test (z test)
All 34 1019.5, p < 0.001 1.29 1.01–1.64 2.07, p < 0.05
Continent
Asia  5 179.7, p < 0.001 1.69 0.77–3.69 1.32, p = 0.19
America 11 80.34, p < 0.001 1.02 0.78–1.33 0.13, p = 0.89
Europe 18 722.89, p < 0.001 1.41 0.97–2.04 1.82, p = 0.07
Diagnostic criteria
Spirometry/Bronchodilator 29 608.06, p < 0.001 1.23 0.98–1.55 1.76, p = 0.14
Physician diagnosis/questionnaire 5 179.48, p < 0.001 1.66 0.84–3.26 1.47, p = 0.09
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Cross sectional 30 552.47, p < 0.0
Cohort 4 160.29, p < 0.0
esigns using forest plot analysis showed the rhomboid depicting
igher prevalence of COPD in current smokers (Fig. S1).
. Comparison of COPD among current smokers and
ormer smokers
.1. Pooled analysis
Thirty four estimates obtained were compared for the COPD
tatus in current and former smokers (Fig. 3). Owing to the large
eterogeneity among the ORs (p < 0.001), a random effects model
as used which showed signiﬁcantly higher prevalence of COPD
OR = 1.29; 95% CI, 1.01–1.64; z = 2.07, p < 0.05) in current smok-
rs compared with former smokers (Table 3 and Fig. 3). The forest
lot analysis revealed the rhomboid of the overall effect depicting
igher prevalence of COPD in current smokers compared to former
mokers.
.2. Stratiﬁed analysis with respect to study locations (Continent)
Stratiﬁed analysis was performed to study the patterns of the
esults obtained due to large heterogeneity among results. Using
andom effects model, higher prevalence of COPD (OR = 1.69; 95%
I, 0.77–3.69; z = 1.32, p = 0.19) was observed in current smokers as
ompared to former smokers in case of Asian studies (Table 3). Simi-
ar trend was observed in studies of American and European origin,
ith higher prevalence of COPD in current smoker for American
OR = 1.02; 95% CI, 0.78–1.33; z = 0.13, p = 0.89) and for European
OR = 1.41; 95% CI, 0.97–2.04; z = 1.82, p = 0.07) studies. The forest
lot analysis for Asian, American and European studies depicted a
imilar trend while studying the rhomboid of the overall effect, with
he analysis results showing higher prevalence of COPD in current
mokers (Fig. S2).
.3. Stratiﬁed analysis by diagnostic criteria of COPD
A random effects model was used for the analysis of the twenty
ine estimates identiﬁed using Spirometry/bronchodilator test for
iagnosis of COPD due to signiﬁcant heterogeneity (p < 0.001). The
revalence of COPD was higher in current smokers compared with
ormer smokers (OR = 1.23; 95% CI, 0.98–1.55; z = 1.76, p = 0.14)
Table 3). The random effects model used for the ﬁve estimates
rom studies using physician diagnosis/questionnaire for the diag-
osis of COPD showed higher prevalence of COPD (OR = 1.66; 95%
I, 0.84–3.26; z = 1.47, p = 0.09) in current smokers as compared to
ormer smokers (Table 3). Similar trend was observed in the for-
st plot analysis with the rhomboid of overall effect representing
igher prevalence in current smokers (Fig. S2).1.17 0.95–1.45 1.47, p = 0.14
1.47 0.53–4.08 0.74, p = 0.46
5.4. Stratiﬁed analysis based on study design
Signiﬁcant heterogeneity was  observed among the odds ratio
obtained from the estimates. Using a random effects model, higher
prevalence of COPD (OR = 1.17; 95% CI, 0.95–1.45; z = 1.47, p = 0.14)
was observed in current smokers compared to former smokers in
cross sectional studies (Table 3). Four estimates from cohort studies
were considered for the meta-analysis, which showed the preva-
lence of COPD to be higher in current smoker (OR = 1.47; 95% CI,
0.53–4.08; z = 0.74, p = 0.46) using a random effects model (Table 3).
The rhomboid of the overall effect of studies based on the study
designs using forest plot analysis represented higher prevalence of
COPD in current smokers (Fig. S2).
6. Comparison of COPD among former smokers and
non-smokers
6.1. Pooled analysis
Thirty two estimates obtained were compared for the COPD
status in former and non-smokers (Fig. 4). A random effects
model was  used, owing to the large heterogeneity among the
ORs (p < 0.001), which showed signiﬁcantly higher prevalence of
COPD in former smokers compared with non-smokers (OR = 2.68;
95% CI, 2.22–3.23; z = 10.35, p < 0.001) (Table 4). The rhomboid
of the overall effect obtained from the meta-analysis showed
higher prevalence of COPD in former smokers as compared to non-
smokers.
6.2. Stratiﬁed analysis with respect to study locations (Continent)
Stratiﬁed analysis was performed due to large heterogene-
ity among results. Using random effects model, a signiﬁcantly
higher prevalence of COPD (OR = 3.89; 95% CI, 3.43–4.42; z = 21.14,
p < 0.001) was observed in former smokers as compared to non-
smokers in case of Asian studies (Table 4). Similar trend was
observed in studies from America and Europe, where prevalence
of COPD was signiﬁcantly higher, for American (OR  = 2.32; 95% CI,
1.74–3.09; z = 5.72, p < 0.001) and for European (OR = 2.65; 95% CI,
1.96–3.58; z = 6.34, p < 0.001) studies, in former smokers compared
with non-smokers. The forest plot analysis for Asian, American and
European studies depicted a similar trend with the rhomboid show-
ing higher prevalence in former smokers (Fig. S3).
6.3. Stratiﬁed analysis by diagnostic criteria of COPDA random effects model was  used for the analysis of the twenty
six estimates identiﬁed using Spirometry/bronchodilator test for
diagnosis of COPD due to signiﬁcant heterogeneity (p < 0.001).
Prevalence of COPD was  signiﬁcantly higher (OR = 3.63; 95% CI,
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NOTE:  Weights are from rand om effects an alysis
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4.01
4.16
2.51
4.05
3.91
2.45
3.74
4.14
3.48
3.79
0.69
3.29
3.63
2.01
3.95
2.86
2.87
1.22
2.96
3.53
3.94
3.25
%
1.1  10
Fig. 4. Forest plot analysis for former v/s non-smokers (pooled data).
Table 4
Comparison of prevalence of COPD between former and non-smokers.
Former smokers v/s non-smokers
No. of estimates Heterogeneity test (Q Test) Odds ratio(OR) 95% C.I. Pooled OR Test (z test)
All 32 283.7, p < 0.001 2.68 2.22–3.23 10.35, p < 0.001
Continent
Asia  5 4.51, p = 0.34 3.89 3.43–4.42 21.14, p < 0.001
America 10 57.92, p < 0.001 2.32 1.74–3.09 5.72, p < 0.001
Europe 17 145.46, p < 0.001 2.65 1.96–3.58 6.34, p < 0.001
Diagnostic criteria
Spirometry/Bronchodilator 26 247.11, p < 0.001 3.63 2.92–4.51 8.05, p < 0.001
Physician diagnosis/questionnaire 6 11.16, p < 0.05 2.49 2.0–3.11 11.67, p < 0.001
Study  design
Cross sectional 27 262.29, p < 0.001 2.64 2.15–3.24 9.29, p < 0.001
Cohort 5 19.80, p < 0.001 3.13 1.24–7.87 2.42, p < 0.05
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.92–4.51; z = 8.05, p < 0.001) in former smokers as compared to
on-smokers (Table 4). The random effects model used for the six
stimates from studies using physician diagnosis/questionnaire for
he diagnosis of COPD showed signiﬁcantly higher prevalence of
OPD, (OR = 2.49; 95% CI, 2.0–3.11; z = 11.67, p < 0.001) in former
mokers as compared to non-smokers (Table 4). Similar trend was
bserved in the forest plot analysis with the rhomboid represent-
ng the overall effect of higher COPD prevalence in former smokers
Fig. S3).
.4. Stratiﬁed analysis based on study design
Using a random effects model, signiﬁcantly higher prevalence
f COPD (OR = 2.64; 95% CI, 2.15–3.24; z = 9.29, p < 0.001) was
bserved in former smokers compared with non-smokers in cross
ectional studies (Table 3). Five estimates from cohort studies
ere considered for the meta-analysis, which showed signiﬁcantly
igher prevalence of COPD in former smokers (OR = 3.13; 95% CI,
.24–7.87; z = 2.42, p < 0.05) using a random effects model (Table 4).
he overall effect of studies based on the study designs using forest
lot analysis showed the rhomboid representing higher prevalence
f COPD in former smokers (Fig. S3).
.5. Funnel plot analysis
Funnel plot analysis was conducted to check for publication bias
mong the estimates from the studies selected for the ﬁnal synthe-
is. Fig. 5 shows the funnel plot of the natural logarithms of OR
stimates against their standard errors for all three comparisons
mong the smoking groups. Using the Egger’s test of publication
ias p = 0.15 was obtained for current and non-smokers, p = 0.74
or current and former smokers and p = 0.90 for former and non-
mokers. Since many studies fall outside the funnel plot, there is a
ossibility for publication bias among the studies.kers; 2: current v/s former smokers; 3: former v/s non-smokers.
7. Discussion
The present meta-analysis, involving 547,391 participants from
forty two  studies found a positive association between smoking
and prevalence of COPD for current smokers as compared to for-
mer  and non-smokers. The results of the pooled analysis also show
large heterogeneity among the different studies with respect to
study location, diagnostic criteria and study designs. The publica-
tion bias was  also observed among studies for current, former and
non-smokers across studies from different locations. Further, this
bias can be attributed to different study design, sample size, study
protocols, criteria followed for current, former and non-smokers
and COPD diagnosis in the ﬁnal synthesized studies.
Smoking and age are widely known as major risk factors for
COPD [18]. A recent study found that the prevalence of COPD
among current smokers (22.4%) and former smokers (24.6%) were
higher than the prevalence among non-smokers (7.0%). Addition-
ally, individuals with ≥20 pack-years exhibited a 3-fold increased
prevalence of COPD as compared to non-smoking individuals after
adjusting for sex and age [19]. Smoking is the main cause of chronic
bronchitis and emphysema, and it is estimated that 80–90% of
the risk to develop COPD is due to smoking [20]. The popula-
tion attributable fraction for smoking as a cause of COPD ranges
from 9.7 to 97.9% [21]. Reports from a Swedish cohort study had
observed population attributable fraction for smoking a cause
of COPD to be 76.2% [22], whereas another cohort study from
Denmark reported the same to be 74.6% [23]. Swedish Obstructive
Lung Disease in Northern Sweden (OLIN) and National Health and
Nutrition Examination Survey (NHANES III) studies reported that
the population-attributable risk of COPD from smoking in these
countries was 45% and 44%, respectively [24,25].Active smoking is a major risk factor for COPD and the mecha-
nism of action of components of cigarette smoke on lung tissue and
parenchyma are multiple [26]. Histological analyses of bronchial
biopsies from patients with mild to moderate COPD show the pres-
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nce of an inﬁltrate of CD8+ lymphocytes in proximal airways.
eutrophils are present in high concentrations in the sputum of
atients with COPD [27]. Cigarette smoke directly stimulates vari-
us types of cells, in particular macrophages [28,29] and epithelial
ells of the airways, thus contributing to increased production
f mediators and cytokines that participate in maintaining the
nﬂammatory reaction [30]. A series of receptor-mediated signal
ransduction pathways are activated by reactive oxygen species
nd tobacco components, resulting in impairment of a variety of cell
ignaling and cytokine networks, subsequently leading to chronic
irway responses with mucus production, airway remodeling, and
lveolar destruction [30].
Different diagnostic criteria for COPD are followed in Global
ccupational Lung Disease GOLD [76], American Thoracic Soci-
ty (ATS), European Respiratory Society (ERS) [31] British Thoracic
ociety (BTS) [32] and National Institute for Health and Care Excel-
ence (NICE) [33]. Diagnosis of COPD is conﬁrmed by FEV1/FVC
atio < 0.7 as per ATS/ERS guidelines and GOLD. BTS criteria for
OPD include both FEV1/FVC <0.7 and FEV1 < 80% predicted val-
es. BTS guidelines also state asthma with chronic obstruction may
e included in COPD. In the NICE guidelines, a FEV1 < 80% of the
redicted value was used for COPD diagnosis. To further fulﬁll the
OPD deﬁnition in NICE guidelines, an FEV1/VC ratio < 0.7 is also
equired.
Strengths of this meta-analysis include the strict inclusion crite-
ia, high score for 86% studies in study quality assessment, the large
umber of subjects analyzed for current, former and non-smokers
nd the representation of study locations across the globe. Another
trength of the present study is the analysis of COPD prevalence
cross various smoking groups (current, former and non-smokers).
he stratiﬁcation of the selected studies by location, study design
nd diagnostic criteria also adds to the strength of the present
tudy. Inclusion of different types of studies into one meta-analysis
ay  also introduce heterogeneity into the results. Limitations of
he present study are (1) retrospective design, (2) lack of individ-
al data sets from each study and (3) non availability of data on
ocio-economic status.
In conclusion, the results from this meta-analysis suggest a pos-
tive association between current smokers and the prevalence of
OPD compared with former and non-smokers. The ﬁndings of the
tudy shows evidence of smoking as a major risk factor for COPD
revalence. The results of the analysis also highlight the dispari-
ies in the diagnostic criteria of COPD across various studies and
moking status, resulting in high heterogeneity among results. The
esults assert the need for common global criteria for diagnosis of
OPD and smoking status in epidemiological and clinical studies,
or a better assessment of this research problem.
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